Addex Therapeutics Ltd · NASDAQ (us_market)
Healthcare · Biotechnology · Switzerland
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-03$8.99 RISE2026-03-20$5.66 PEAK2026-04-14$7.20 132d | -37.0% 107d | Missed | Missed | — | — | +27.2% 25d | Missed |
DROP2025-10-17$10.95 RISE2025-12-15$7.01 PEAK2026-01-13$8.80 88d | -36.0% 59d | Missed | Missed | — | — | +25.5% 29d | Missed |
DROP2025-06-06$10.23 RISE2025-08-14$7.52 PEAK2025-10-17$10.95 133d | -26.5% 69d | Missed | Missed | — | — | +45.6% 64d | Missed |
DROP2025-02-24$9.00 RISE2025-05-29$7.57 PEAK2025-06-06$10.23 102d | -15.9% 94d | Missed | Missed | — | — | +35.1% 8d | Missed |
DROP2025-02-24$9.00 RISE2025-04-09$6.51 PEAK2025-06-06$10.23 102d | -27.7% 44d | Missed | Missed | — | — | +57.1% 58d | Missed |
DROP2025-02-24$9.00 RISE2025-04-08$6.51 PEAK2025-06-06$10.23 102d | -27.7% 43d | Missed | Missed | — | — | +57.1% 59d | Missed |
DROP2024-10-24$11.56 RISE2025-02-11$6.73 PEAK2025-02-24$9.00 123d | -41.8% 110d | Missed | Missed | — | — | +33.7% 13d | Missed |
DROP2024-08-27$11.58 RISE2024-12-31$7.00 PEAK2025-02-24$9.00 181d | -39.6% 126d | Missed | Missed | — | — | +28.6% 55d | Missed |
DROP2024-08-27$11.58 RISE2024-09-27$9.05 PEAK2024-10-24$11.56 58d | -21.8% 31d | Missed | Missed | — | — | +27.7% 27d | Missed |
DROP2024-04-09$27.90 RISE2024-08-05$7.20 PEAK2024-08-27$11.58 140d | -74.2% 118d | Missed | Missed | — | — | +60.8% 22d | Missed |
DROP2024-04-09$27.90 RISE2024-06-24$7.70 PEAK2024-08-27$11.58 140d | -72.4% 76d | Missed | Missed | — | — | +50.4% 64d | Missed |
DROP2024-04-09$27.90 RISE2024-04-29$7.54 PEAK2024-05-14$9.45 35d | -73.0% 20d | Missed | Missed | — | — | +25.3% 15d | Missed |
DROP2024-01-29$13.10 RISE2024-03-01$9.05 PEAK2024-04-09$27.90 71d | -30.9% 32d | Missed | Missed | — | — | +208.3% 39d | Missed |
DROP2023-08-11$11.32 RISE2023-12-18$5.15 PEAK2024-01-29$13.10 171d | -54.5% 129d | Missed | Missed | — | — | +154.4% 42d | Missed |
DROP2023-07-13$12.30 RISE2023-11-09$5.26 PEAK2024-01-29$13.10 200d | -57.2% 119d | Missed | Missed | — | — | +149.0% 81d | Missed |
1–15 / 45 1 / 3 | |||||||
No scored news yet for a sentiment trend.
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call April 30, 2026 10:00 AM EDTCompany ParticipantsTimothy Dyer - Co-Founder, CEO & DirectorMikhail...
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued to reposition dipraglurant mGlu5 NAM for brain injury recoveryEntered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryRegained rights to phase 2 mGlu2 PAM asset, ADX71149Partner, Indivior advanced GABAB PAM substance use disorders program successfully t
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.50) per share. This is a 9.49 percent decrease over losses of $(1.37) per share from the same period last year. The company reported $20.020 thousand in
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chr
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allost
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. “These important data i
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) coul
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 recepto
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) initially entered into on January 30, 2024. The at-the-market offerin
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ADXN | -5.00% | -8.65% | -13.86% | -17.08% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -7.97% | -2.94% | -10.42% | -29.77% |